查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1925880

寡核苷酸藥物CDMO服務市場依工作流程階段、寡核苷酸模式、生產規模、技術平台、合約模式和最終用戶分類－2026-2032年全球預測

Oligonucleotide Drug CDMO Services Market by Workflow Stage, Oligonucleotide Modality, Production Scale, Technology Platform, Contract Model, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，寡核苷酸藥物 CDMO 服務市場價值將達到 23 億美元，到 2026 年將成長至 25.2 億美元，到 2032 年將達到 43.4 億美元，複合年成長率為 9.47%。

關鍵市場統計數據
基準年 2025 23億美元
預計年份：2026年 25.2億美元
預測年份 2032 43.4億美元
複合年成長率 (%) 9.47%

為高階主管和技術決策者提供寡核苷酸CDMO服務的策略性介紹

隨著寡核苷酸療法從利基研究工具發展成為精準醫療的基石治療方法，合約研發生產機構（CDMO）在支持這一發展進程中的作用日益重要。本文重點闡述了外包夥伴關係如何幫助敏捷的製程開發、監管合規以及不同治療方法的規模化生產，並將CDMO服務置於更廣泛的生物製藥創新生態系統中。文章強調，供應商需要平衡深厚的技術能力和靈活的商業模式，以滿足申辦者的優先事項。

寡核苷酸CDMO服務轉型的關鍵轉折點，以及產業相關人員為維持競爭優勢所必須採取的適應措施。

寡核苷酸CDMO產業正經歷多重變革，這些變革正在重塑供應商的能力和申辦者的選擇標準。諸如改進的偶聯化學、先進的固相和酶促合成方法以及遞送技術的創新等技術進步，在增加研發項目技術複雜性的同時，也創造了新的治療機會。這些進步提高了CDMO在專業設施、分析深度和跨學科專業知識方面的要求。

2025年美國關稅政策變化對寡核苷酸CDMO企業、供應鏈和合作夥伴經濟的累積影響

2025年實施的關稅調整為全球供應鏈帶來了新的摩擦，對寡核苷酸的研發和生產活動產生了重大影響。直接的營運影響體現在對上游工程原料採購的持續審查，特別是對以往可以自由跨境流通的特殊試劑和一次性組件的採購。採購部門已透過建立庫存緩衝和對多家供應商進行資質審核來應對，但這給營運資金帶來了壓力，並需要與生產計劃密切協調，以避免供應中斷。

關鍵細分洞察：揭示不同的工作流程階段、模式類型、生產規模、技術平台、最終用戶和合約模式如何需要差異化的CDMO策略。

了解市場區隔對於CDMO策略至關重要，因為專案需求會隨著研發階段和治療方式的不同而顯著變化。工作流程階段的考量涵蓋了從早期研發活動（包括發現和臨床前研究，需要快速迭代和靈活的實驗室規模服務）到臨床開發（I期、II期和III期研究各有不同的需求，強調可靠的分析方案、符合GMP規範的生產和規模化過渡）再到商業化生產（長期供應可靠性和檢驗的大規模生產過程至關重要）。每個工作流程階段對速度、文件和設施合格等方面都有不同的重點。

區域觀點：全球市場監管、基礎設施和人才差異如何影響寡核苷酸CDMO策略和投資重點

地理位置對寡核苷酸計畫的開發和生產方式有顯著影響。在美洲，由於申辦公司高度集中且臨床活動活躍，因此對高產能的GMP設施、深厚的監管專業知識和整合分析技術的需求不斷成長。接近性大型藥物研發公司能夠加速夥伴關係的建立並支持複雜的技術轉移，而本地人才儲備和成熟的供應鏈則在規模化生產和商業化準備方面提供了比較優勢。

從策略層面深入剖析寡核苷酸CDMO生態系的競爭定位、能力差異化與夥伴關係模式。

寡核苷酸CDMO領域的供應商策略正沿著技術深度、服務廣度和商業性柔軟性三個維度呈現多元化發展。一些機構專注於提供一體化服務，投資於涵蓋從藥物發現分析到商業化生產的端到端能力，以吸引那些尋求與單一供應商保持長期合作關係的申辦者。這些供應商優先考慮跨職能團隊、模組化設施和內部分析開發，以減少摩擦並加快技術轉移進程。

為行業領導者提供切實可行的建議，以增強其在寡核苷酸CDMO合約中的韌性、加速開發並創造價值。

領導者應優先建構具有韌性的供應鏈，具體措施包括對關鍵試劑的多個供應商進行資格認證，並投資開展供應商風險評估，評估內容涵蓋地緣政治、物流和品質等各個方面。同時，採用模組化設施設計和基於平台的製程模板可以減少技術轉移所需的時間和成本，並加快規模化生產。此外，投資分析技術和自動化可以降低批次差異，提高可追溯性，並增強監管合應對力。

透明的調查方法解釋了用於得出研究結果的資料收集、檢驗和分析方法，確保了研究結果的可重複性和可靠性。

本研究結合了定性和結構化的證據收集方法，以提供平衡且以實踐者為導向的分析。主要研究包括對贊助機構和服務供應商的高級技術、營運和商務主管進行訪談，討論重點是流程開發實踐、技術實施和合約談判的優先事項。這些訪談輔以專家圓桌討論和主題後續檢驗，以驗證新出現的主題。

簡要總結了寡核苷酸開發和CDMO關係相關相關人員的戰略意義和優先事項。

寡核苷酸療法仍展現出巨大的科學潛力，但要大規模地實現這一潛力，需要研發人員與專業生產合作夥伴之間的有效協作。那些在特定療法化學和偶聯方法方面擁有卓越技術，並具備靈活運作模式，能夠支持從藥物發現到商業化供應的全流程開發的供應商，將在該領域佔據優勢。反過來，申辦方也將受益於採用一套嚴謹的合作夥伴選擇框架，該框架強調監管合規記錄、分析深度和營運靈活性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 寡核苷酸藥物CDMO服務市場依工作流程階段分類

  • 臨床開發
    • I期試驗
    • 第二階段
    • 第三階段
  • 商業生產
  • 研究與開發
    • 藥物發現
    • 臨床前

9. 寡核苷酸藥物CDMO服務市場（以寡核苷酸給藥方式分類）

  • 反義寡核苷酸
    • 蓋普瑪
    • Mixmar
    • 3D阻擋器
  • 適體
    • DNA適體
    • RNA適體
  • CpG寡核苷酸
  • 微型RNA
  • siRNA

第10章：寡核苷酸藥物CDMO服務市場（依生產規模分類）

  • 臨床量表
  • 商業規模
  • 實驗室規模
  • 中試規模

11. 寡核苷酸藥物CDMO服務市場（依技術平台分類）

  • 鍵合技術
    • GalNAc結合
    • 脂質奈米顆粒結合
  • 酵素合成
  • 固相合成

12. 寡核苷酸藥物CDMO服務市場（依合約類型分類）

  • 一體化CDMO
  • 單一服務供應商
    • 僅提供分析服務的供應商
    • 僅開發服務提供者
    • 僅生產製造的供應商

13. 寡核苷酸藥物CDMO服務市場（依最終用戶分類）

  • 學術研究機構
  • 生物製藥公司
  • 製藥公司

14. 寡核苷酸藥物CDMO服務市場（依地區分）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

15. 寡核苷酸藥物CDMO服務市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

16. 各國寡核苷酸藥物CDMO服務市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

17. 美國寡核苷酸藥物CDMO服務市場

第18章：中國寡核苷酸藥物CDMO服務市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AGC Biologics, Inc.
  • Alcami Corporation
  • Catalent, Inc.
  • CordenPharma International GmbH
  • Eurofins Scientific
  • GenScript Biotech Corporation
  • Kaneka Eurogentec SA
  • Lonza Group Ltd.
  • Merck KGaA
  • Patheon Manufacturing Services LLC
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific, Inc.
  • WuXi AppTec Co., Ltd.
Product Code: MRR-4F7A6D4FDA9E

The Oligonucleotide Drug CDMO Services Market was valued at USD 2.30 billion in 2025 and is projected to grow to USD 2.52 billion in 2026, with a CAGR of 9.47%, reaching USD 4.34 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.30 billion
Estimated Year [2026] USD 2.52 billion
Forecast Year [2032] USD 4.34 billion
CAGR (%) 9.47%

A strategic introduction to oligonucleotide CDMO services framed for senior executives and technical decision-makers

Oligonucleotide therapeutics have evolved from niche research tools into a foundational modality for precision medicine, and contract development and manufacturing organizations play an increasingly central role in enabling that evolution. This introduction situates CDMO services within the broader biopharmaceutical innovation ecosystem by highlighting how outsourcing partnerships enable nimble process development, regulatory readiness, and scale transitions for a diverse set of modalities. It underscores the need for providers to balance deep technical capabilities with flexible commercial models to meet sponsor priorities.

As discovery teams push novel mechanisms of action and developers prepare candidates for clinical progression, the CDMO value proposition must address time-to-clinic, analytical rigor, and manufacturability. This requires integrated approaches that span oligonucleotide design translation, conjugation chemistry, and platform-based manufacturing. Concurrently, executives must weigh strategic trade-offs between single-service specialists and integrated CDMOs, ensuring alignment of risk tolerance, cost structure, and long-term supply security.

The introduction closes by framing the remainder of the report: it will examine landscape shifts, policy impacts, segmentation dynamics, regional considerations, competitive behaviors, and pragmatic actions that industry leaders can deploy to convert scientific promise into reliable clinical and commercial supply.

Transformative shifts reshaping oligonucleotide CDMO services and how industry stakeholders must adapt to sustain competitive advantage

The oligonucleotide CDMO landscape is undergoing several concurrent shifts that are transforming provider capabilities and sponsor selection criteria. Technological advancements such as improved conjugation chemistries, refined solid-phase and enzymatic synthesis options, and delivery innovations are increasing the technical complexity of development programs while unlocking new therapeutic opportunities. These advances raise the bar for CDMOs in terms of specialized equipment, analytical depth, and cross-disciplinary expertise.

Commercial dynamics are evolving in tandem. Sponsors are increasingly seeking partners who can deliver end-to-end solutions that accelerate clinical timelines and mitigate regulatory risk. This has benefited integrated CDMO models that combine development, analytics, and manufacturing under one governance structure, but it also creates space for niche single-service providers that deliver deep expertise in areas like analytical method development or specialized conjugation technologies. Strategic collaboration patterns are emerging, with alliances, joint ventures, and risk-sharing agreements supplementing traditional fee-for-service arrangements.

Workforce and operational imperatives are also changing. Skilled talent in oligonucleotide process chemistry, analytical science, and regulatory affairs is at a premium, and automation coupled with digital process control is becoming essential to reduce variability and improve reproducibility. As a result, CDMOs that invest in modular facilities, scalable processes, and cross-functional teams are better positioned to meet sponsor expectations and capture new program flow-through.

The cumulative effects of United States tariff policy changes in 2025 on oligonucleotide CDMO operations, supply chains, and partner economics

Tariff changes implemented in 2025 introduced a new set of frictions into global supply chains that are material to oligonucleotide development and manufacturing activities. The immediate operational consequence has been a reassessment of upstream raw material sourcing, particularly for specialty reagents and single-use components that historically moved freely across borders. Procurement teams responded by increasing inventory buffers and qualifying multiple suppliers, which introduced working capital pressures and required closer coordination with manufacturing schedules to avoid disruption.

Beyond procurement, tariffs influenced strategic location decisions for both sponsors and CDMOs. Organizations reevaluated nearshoring and onshoring strategies to reduce exposure to cross-border duties and to secure continuity of supply for critical campaign schedules. This shift has amplified the importance of facility flexibility and multi-site qualification to enable rapid transfer of processes between jurisdictions when needed. Regulatory interactions intensified as companies sought clarity on classification and valuation rules that affect duty calculation, prompting more proactive engagement with customs and trade advisors to prevent delays in clinical and commercial supply chains.

The tariffs also affected commercial arrangements. Sponsors and providers renegotiated contractual terms to allocate cost and delivery risks more explicitly, moving toward clauses that address duty pass-throughs, lead time adjustments, and supplier substitution protocols. In sum, the 2025 tariff changes did not merely increase cost overheads; they altered procurement strategies, facility planning, risk allocation, and the speed at which projects can progress from development into clinical or commercial supply.

Key segmentation insights that unpack how distinct workflow stages, modality types, production scales, technology platforms, end users, and contract models demand differentiated CDMO strategies

Understanding segmentation is essential for CDMO strategy because program needs diverge widely across development stage and modality. Workflow stage considerations range from early Research and Development activity, which includes Discovery and Preclinical work requiring rapid iteration and flexible laboratory-scale services, to Clinical Development with distinct Phase I, Phase II, and Phase III requirements that emphasize robust analytical packages, GMP-compliant manufacturing, and scale transitions, and onward to Commercial Manufacturing where long-term supply reliability and validated large-scale processes are paramount. Each workflow stage drives different prioritization of speed, documentation, and facility qualification.

Modality-specific requirements further differentiate provider capabilities. Antisense oligonucleotides include the subtypes gapmers, mixmers, and steric blockers, each carrying unique synthesis and analytical demands, while aptamers, which can be DNA or RNA-based, require particular attention to folding, stability, and sequence-specific purification strategies. Other modalities such as CpG oligonucleotides, microRNA constructs, and small interfering RNA introduce distinct chemistries, conjugation needs, and formulation challenges that influence process design and quality control workflows.

Production scale considerations affect capital planning and operational models. Laboratory-scale and pilot-scale work support discovery and early development activities and favor flexible, multi-purpose suites, while clinical-scale work requires controlled GMP environments with validated processes, and commercial-scale manufacturing demands robust supply chains, capacity planning, and technology transfer governance. Technology platform choices-spanning solid-phase synthesis, enzymatic synthesis, and conjugation technologies such as GalNAc and lipid nanoparticle approaches-determine upstream and downstream unit operations, analytical method complexity, and facility layout.

End users shape engagement models and service expectations. Academic and research institutes often require shorter-term, high-flexibility engagements with a focus on method development and proof-of-concept material, whereas biopharmaceutical and pharmaceutical companies seek partners that can scale programs through clinical development and into commercial supply with integrated quality and regulatory support. Contract model dynamics also matter: integrated CDMO offerings attract sponsors looking for end-to-end continuity, while single-service providers, including analytical-only, development-only, or manufacturing-only specialists, appeal to programs seeking targeted expertise or capacity supplementation.

Regional perspectives that illuminate how differing regulatory, infrastructure, and talent dynamics across global markets influence oligonucleotide CDMO strategies and investment priorities

Geographic context materially affects the way oligonucleotide programs are developed and manufactured. In the Americas, a dense concentration of sponsors and advanced clinical activity has driven demand for high-capacity GMP facilities, deep regulatory expertise, and integrated analytics. Proximity to major drug developers often accelerates partnership formation and supports complex technology transfers, while local talent pools and established supply chains provide comparative advantages for scale-up and commercial readiness.

In Europe, Middle East & Africa, manufacturing clusters offer strong regulatory frameworks and skilled workforces, but sponsors often face more fragmented market dynamics and country-level regulatory nuances that require tailored regulatory strategies. Investment trends in this region favor flexible facilities that can serve both regional and global needs, and collaboration with academic centers supports modality innovation. Moreover, regional incentives and collaborative consortia can reduce entry barriers for sponsors seeking early clinical activity.

Asia-Pacific presents a mix of rapidly expanding manufacturing capacity and significant investments in specialized capabilities. Several countries in the region combine cost-efficient operations with growing technical expertise in oligonucleotide synthesis and conjugation technologies. Regulatory harmonization efforts are progressing, but differences in dossier expectations and inspection regimes mean that global sponsors and CDMOs must carefully plan submissions and quality agreements. Together, these regional dynamics influence decisions on where to house innovation, where to scale commercial supply, and how to structure multi-jurisdictional manufacturing networks.

Strategic company-level insights that explain competitive positioning, capability differentiation, and partnership models shaping the oligonucleotide CDMO ecosystem

Provider strategies in the oligonucleotide CDMO space vary along axes of technical depth, service breadth, and commercial flexibility. Some organizations emphasize integrated service delivery, investing in end-to-end capabilities that span discovery analytics through commercial manufacturing to appeal to sponsors seeking single-vendor continuity. These providers prioritize cross-functional teams, modular facilities, and in-house analytical development to reduce transfer friction and accelerate timelines.

Conversely, specialized single-service providers focus on niche strengths such as high-resolution analytical platforms, bespoke conjugation expertise, or pilot-scale process optimization. Their value proposition rests on deep domain expertise and the ability to serve as high-quality adjuncts to integrated partners or sponsor in-house teams. Strategic alliances and white-label arrangements are increasingly common, with companies combining complementary capabilities to offer hybrid solutions that balance depth and breadth.

Leadership in this sector increasingly depends on investment priorities that extend beyond capacity. Effective CDMOs demonstrate strong quality systems, regulatory track records, and robust data integrity practices. They also cultivate program management excellence and transparent communication to reduce sponsor risk perception. Finally, companies that succeed are those that can adapt contract models-from time-and-materials arrangements to outcome-oriented partnerships-while maintaining clarity on intellectual property stewardship and supply continuity.

Practical and actionable recommendations for industry leaders to strengthen resilience, accelerate development, and capture value in oligonucleotide CDMO engagements

Leaders should prioritize building resilient supply chains by qualifying multiple suppliers for critical reagents and by investing in supplier risk assessments that include geopolitical, logistical, and quality dimensions. Coupled with this, adopting modular facility designs and platform-based process templates reduces time and cost associated with technology transfer and enables faster scale transitions. In parallel, investment in analytics and automation reduces batch variability, improves traceability, and enhances regulatory readiness.

From a strategic partnership perspective, sponsors and providers should align early on scope, success metrics, and risk allocation to prevent downstream disputes. This includes clear contractual language on change control, duty and tariff pass-through, and contingency manufacturing plans. Investment in workforce development is equally important; upskilling scientists and engineers in oligonucleotide-specific chemistries, conjugation methods, and regulatory expectations will reduce dependency on external specialists and shorten program timelines.

Finally, organizations should adopt a portfolio approach to facility and capability investments, balancing core competencies with targeted collaborations to fill capability gaps. Prioritizing sustainability measures, data-centric quality systems, and proactive regulatory engagement will further strengthen competitive positioning and ensure reliable supply for clinical and commercial programs.

A transparent research methodology describing data collection, validation, and analytical approaches used to derive insights while ensuring reproducibility and credibility

This research combined qualitative and structured evidence-gathering approaches to produce a balanced, practitioner-oriented analysis. Primary research included interviews with senior technical, operational, and commercial leaders from sponsor organizations and service providers, with discussions focused on process development practices, technology adoption, and contract negotiation priorities. These interviews were supplemented by expert roundtables and targeted follow-ups to validate emerging themes.

Secondary research comprised a review of publicly disclosed regulatory guidance, peer-reviewed literature on oligonucleotide technologies, corporate disclosures, and industry-issued technical white papers. Careful source triangulation ensured that observations were cross-checked across multiple inputs, and analytical frameworks were applied to identify patterns across workflow stages, modalities, production scales, and regional contexts. Where appropriate, scenario analysis was used to test the operational implications of policy changes and supply chain disruptions.

To maintain methodological rigor, findings were iteratively reviewed with subject-matter experts and underwent an internal quality assurance process that emphasized traceability of claims, clarity of assumptions, and explicit statement of limitations. The methodology section documents interview scopes, secondary data categories, and validation steps so that readers can assess the robustness of the conclusions and apply them to their own strategic contexts.

A concise conclusion synthesizing the strategic implications and priorities for stakeholders engaged in oligonucleotide development and CDMO relationships

Oligonucleotide therapeutics continue to present high scientific promise, but realizing that promise at scale depends on effective collaboration between developers and specialized manufacturing partners. The landscape favors providers who combine technical excellence in modality-specific chemistries and conjugation approaches with flexible operational models capable of supporting everything from discovery to commercial supply. Equally, sponsors benefit from adopting disciplined partner selection frameworks that emphasize regulatory track records, analytical depth, and operational agility.

Policy shifts and trade dynamics have added new layers of complexity to supply chain management and contracting, prompting more explicit risk allocation and a reevaluation of geographic strategies. As such, resilience-enabled by supplier diversification, modular facilities, and strong data systems-has become a central strategic objective. Looking ahead, the most successful organizations will be those that translate technological innovation into reproducible, scalable processes while aligning commercial arrangements to share risk sensibly and preserve program momentum.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oligonucleotide Drug CDMO Services Market, by Workflow Stage

  • 8.1. Clinical Development
    • 8.1.1. Phase I
    • 8.1.2. Phase II
    • 8.1.3. Phase III
  • 8.2. Commercial Manufacturing
  • 8.3. Research And Development
    • 8.3.1. Discovery
    • 8.3.2. Preclinical

9. Oligonucleotide Drug CDMO Services Market, by Oligonucleotide Modality

  • 9.1. Antisense Oligonucleotides
    • 9.1.1. Gapmers
    • 9.1.2. Mixmers
    • 9.1.3. Steric Blockers
  • 9.2. Aptamers
    • 9.2.1. DNA Aptamers
    • 9.2.2. RNA Aptamers
  • 9.3. CpG Oligonucleotides
  • 9.4. MiRNA
  • 9.5. SiRNA

10. Oligonucleotide Drug CDMO Services Market, by Production Scale

  • 10.1. Clinical Scale
  • 10.2. Commercial Scale
  • 10.3. Laboratory Scale
  • 10.4. Pilot Scale

11. Oligonucleotide Drug CDMO Services Market, by Technology Platform

  • 11.1. Conjugation Technologies
    • 11.1.1. GalNAc Conjugation
    • 11.1.2. Lipid Nanoparticle Conjugation
  • 11.2. Enzymatic Synthesis
  • 11.3. Solid-Phase Synthesis

12. Oligonucleotide Drug CDMO Services Market, by Contract Model

  • 12.1. Integrated CDMO
  • 12.2. Single-Service Provider
    • 12.2.1. Analytical-Only Providers
    • 12.2.2. Development-Only Providers
    • 12.2.3. Manufacturing-Only Providers

13. Oligonucleotide Drug CDMO Services Market, by End User

  • 13.1. Academic And Research Institutes
  • 13.2. Biopharmaceutical Companies
  • 13.3. Pharmaceutical Companies

14. Oligonucleotide Drug CDMO Services Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Oligonucleotide Drug CDMO Services Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Oligonucleotide Drug CDMO Services Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Oligonucleotide Drug CDMO Services Market

18. China Oligonucleotide Drug CDMO Services Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AGC Biologics, Inc.
  • 19.6. Alcami Corporation
  • 19.7. Catalent, Inc.
  • 19.8. CordenPharma International GmbH
  • 19.9. Eurofins Scientific
  • 19.10. GenScript Biotech Corporation
  • 19.11. Kaneka Eurogentec S.A.
  • 19.12. Lonza Group Ltd.
  • 19.13. Merck KGaA
  • 19.14. Patheon Manufacturing Services LLC
  • 19.15. Samsung Biologics Co., Ltd.
  • 19.16. Thermo Fisher Scientific, Inc.
  • 19.17. WuXi AppTec Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COMMERCIAL MANUFACTURING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GAPMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GAPMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GAPMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MIXMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MIXMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MIXMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY STERIC BLOCKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY STERIC BLOCKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY STERIC BLOCKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DNA APTAMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DNA APTAMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DNA APTAMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RNA APTAMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RNA APTAMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RNA APTAMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CPG OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CPG OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CPG OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SIRNA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SIRNA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SIRNA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COMMERCIAL SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY LABORATORY SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY LABORATORY SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY LABORATORY SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PILOT SCALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PILOT SCALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PILOT SCALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GALNAC CONJUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GALNAC CONJUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GALNAC CONJUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY LIPID NANOPARTICLE CONJUGATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY LIPID NANOPARTICLE CONJUGATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY LIPID NANOPARTICLE CONJUGATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ENZYMATIC SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SOLID-PHASE SYNTHESIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY INTEGRATED CDMO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY INTEGRATED CDMO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY INTEGRATED CDMO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANALYTICAL-ONLY PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANALYTICAL-ONLY PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANALYTICAL-ONLY PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DEVELOPMENT-ONLY PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DEVELOPMENT-ONLY PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY DEVELOPMENT-ONLY PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MANUFACTURING-ONLY PROVIDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MANUFACTURING-ONLY PROVIDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY MANUFACTURING-ONLY PROVIDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY BIOPHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 121. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 122. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 123. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 124. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 125. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 126. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 127. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 128. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 129. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 130. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 131. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 132. AMERICAS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 133. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 136. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 138. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 148. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 150. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 152. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 182. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 183. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 184. EUROPE OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 196. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 209. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 210. AFRICA OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 211. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 212. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 213. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 214. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 215. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 216. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 217. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 218. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GLOBAL OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 225. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 227. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 228. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 229. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 230. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 231. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 232. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 233. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 234. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 235. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 236. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 237. ASEAN OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 240. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 241. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 242. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 243. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 244. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 245. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 246. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 247. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 248. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 249. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 250. GCC OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 252. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 253. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 254. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 255. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 256. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 257. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 258. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 259. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 260. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 261. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 262. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY WORKFLOW STAGE, 2018-2032 (USD MILLION)
  • TABLE 266. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CLINICAL DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 267. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY RESEARCH AND DEVELOPMENT, 2018-2032 (USD MILLION)
  • TABLE 268. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY OLIGONUCLEOTIDE MODALITY, 2018-2032 (USD MILLION)
  • TABLE 269. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, 2018-2032 (USD MILLION)
  • TABLE 270. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY APTAMERS, 2018-2032 (USD MILLION)
  • TABLE 271. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY PRODUCTION SCALE, 2018-2032 (USD MILLION)
  • TABLE 272. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY TECHNOLOGY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 273. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONJUGATION TECHNOLOGIES, 2018-2032 (USD MILLION)
  • TABLE 274. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY CONTRACT MODEL, 2018-2032 (USD MILLION)
  • TABLE 275. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY SINGLE-SERVICE PROVIDER, 2018-2032 (USD MILLION)
  • TABLE 276. BRICS OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 277. G7 OLIGONUCLEOTIDE DRUG CDMO SERVICES MARKET SIZE, BY COUNTRY,